Science & Enterprise subscription

Follow us on Twitter

  • Results from a clinical trial show a combination of two synthetic antibodies reduces deaths in hospitalized Covid-1… https://t.co/AtztCHfZLl
    about 10 hours ago
  • New post on Science and Enterprise: Antibodies Help Some Hospitalized Covid-19 Patients https://t.co/lJhns0fZzJ #Science #Business
    about 10 hours ago
  • https://t.co/BUeUy0ajO3 ... Crocodile on the Tarcoles River in Costa Rica, for #NaturePhotographyDay ... February 2020.
    about 1 day ago
  • https://t.co/mtU98giel5 Oystercatcher for #NaturePhotographyDay ... Cape May, New Jersey. June 2019.
    about 1 day ago
  • Two biotechnology companies are designing therapies to deliver edited genes to treat Friedreich’s ataxia and amyotr… https://t.co/7tbDhyf5lv
    about 1 day ago

Please share Science & Enterprise

Gene Therapy Company Starts-Up, Gains $200M

Adeno-associated virus

A new company is underway commercializing research on gene therapies for inherited diseases, staked to an initial investment of $200 million. . . . → Read More: Gene Therapy Company Starts-Up, Gains $200M

New Biotech Creating Precision Cancer Therapies

DNA analysis graphic

A biotechnology company began work in public to develop new treatments that target proteins responsible for gene expression, beginning with cancer. . . . → Read More: New Biotech Creating Precision Cancer Therapies

Early-Stage Life Science Investment Fund Raises $515M

Growing money

A new venture investment fund raised $515 million for life science start-ups, and its business incubator partner added five biotechs to its seed round portfolio. . . . → Read More: Early-Stage Life Science Investment Fund Raises $515M

New Biotech Developing Synthetic Long-Term RNA

Avak Kahvejian

A new enterprise, created by a life science venture capital company, began work on developing therapies with long-acting synthetic RNA. . . . → Read More: New Biotech Developing Synthetic Long-Term RNA

AI Gene Therapy Platform Gains $100M in Early Funds

Adeno-associated virus

A company using machine learning to create engineered viruses to deliver gene therapies is raising $100 million in its first venture funding round. . . . → Read More: AI Gene Therapy Platform Gains $100M in Early Funds

Cell Therapy Mfring Company Raises $82M in Venture Funds

T-cells and cancer cells

A company developing an automated yet personalized manufacturing platform for cell therapies is raising $82 million in its second venture funding round. . . . → Read More: Cell Therapy Mfring Company Raises $82M in Venture Funds

Start-Up Designing Synthetic DNA for Gene Therapies

DNA puzzle

A new biotechnology company is underway creating gene therapies for inherited diseases delivered with synthetic DNA instead of benign viruses. . . . → Read More: Start-Up Designing Synthetic DNA for Gene Therapies

Synthetic DNA Company Raises $24M in Early Funds

DNA illustration

A company with a technology it says is simpler and more like natural processes to produce synthetic DNA is raising $24 million in its first venture round. . . . → Read More: Synthetic DNA Company Raises $24M in Early Funds

Nine Campuses Join Rural Food Research Fund

Grain storage structure

Nine universities in the U.S. are taking part in a program supporting research and entrepreneurs developing food and agricultural solutions in rural areas. . . . → Read More: Nine Campuses Join Rural Food Research Fund

Infographic – Global Venture Funds Hit Record High

Global venture funds, Q1 2021

Venture investing, a key source of capital for research-based companies, hit a record high level worldwide in the first quarter of 2021. . . . → Read More: Infographic – Global Venture Funds Hit Record High